Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Carregando...
Citações na Scopus
25
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
CHAU, Ian
PARK, Joon Oh
RYOO, Baek-Yeol
YEN, Chia-Jui
POON, Ronnie
PASTORELLI, Davide
BLANC, Jean-Frederic
KUDO, Masatoshi
HATANO, Etsuro
Citação
BRITISH JOURNAL OF CANCER, v.119, n.1, p.19-26, 2018
Resumo
BACKGROUND: Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. METHODS: Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. RESULTS: Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621; P < 0.0001) and to radiographic progression (HR 0.613; P < 0.0001) favoured ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29; P < 0.0001) and 12 weeks (OR 2.28, 95% CI 1.47, 3.53; P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001). More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P < 0.0001). CONCLUSIONS: Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.
Palavras-chave
Referências
- Amini A, 2012, CURR CANCER DRUG TAR, V12, P23, DOI 10.2174/156800912798888956
- Borzio M, 2018, HEPATOLOGY, V67, P2215, DOI 10.1002/hep.29662
- Chan SL, 2009, J CLIN ONCOL, V27, P446, DOI 10.1200/JCO.2008.18.8151
- Chen LT, 2005, ALIMENT PHARM THER, V22, P217, DOI 10.1111/j.1365-2036.2005.02547.x
- CHOI TK, 1984, CANCER, V53, P401, DOI 10.1002/1097-0142(19840201)53:3<401::AID-CNCR2820530306>3.0.CO;2-L
- Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
- Gomaa AI, 2009, WORLD J GASTROENTERO, V15, P1301, DOI 10.3748/wjg.15.1301
- Jelic S, 2010, ANN ONCOL, V21, pv59, DOI 10.1093/annonc/mdq166
- Kim BK, 2011, LIVER INT, V31, P369, DOI 10.1111/j.1478-3231.2010.02368.x
- Lee S, 2015, J HEPATOCELL CARCINO, V2, P39, DOI 10.2147/JHC.S79353
- Liu L, 2016, SCI REP-UK, V6, DOI 10.1038/srep19851
- Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.121, 10.1038/nrclinonc.2015.103]
- Manghisi G, 1998, HEPATOLOGY, V28, P751
- MATSUMOTO Y, 1976, AM J SURG, V132, P325, DOI 10.1016/0002-9610(76)90385-8
- Memon K, 2012, J HEPATOL, V56, P1112, DOI 10.1016/j.jhep.2011.11.020
- Personeni N, 2012, J HEPATOL, V57, P101, DOI 10.1016/j.jhep.2012.02.016
- Pons Fernando, 2005, HPB (Oxford), V7, P35, DOI 10.1080/13651820410024058
- Riaz A, 2009, J CLIN ONCOL, V27, P5734, DOI 10.1200/JCO.2009.23.1282
- Spratlin JL, 2010, J CLIN ONCOL, V28, P780, DOI 10.1200/JCO.2009.23.7537
- Tangkijvanich P, 2000, J CLIN GASTROENTEROL, V31, P302, DOI 10.1097/00004836-200012000-00007
- Tugues S, 2011, MOL ASPECTS MED, V32, P88, DOI 10.1016/j.mam.2011.04.004
- Vora SR, 2009, ONCOLOGIST, V14, P717, DOI 10.1634/theoncologist.2009-0038
- Wang NY, 2014, ASIAN PAC J CANCER P, V15, P1539, DOI 10.7314/APJCP.2014.15.4.1539
- Zhang XF, 2009, EJSO-EUR J SURG ONC, V35, P622, DOI 10.1016/j.ejso.2008.08.003
- Zhu AX, 2015, LANCET ONCOL, V16, P859, DOI 10.1016/S1470-2045(15)00050-9
- Zhu AX, 2013, CLIN CANCER RES, V19, P6614, DOI 10.1158/1078-0432.CCR-13-1442
- Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30